Clinically Relevant SCLC Models with Key Mutations & Molecular Characteristics
Optimize the development of your SCLC treatments with the premier in vivo screening platform. This platform includes a meticulously curated collection of robust PDX models, both pretreated and treatment-naïve, reflecting real-world responses to combination therapies such as carboplatin + etoposide.
Clinically Relevant Models
Living bank of clinically relevant PDX models with key mutations and molecular characteristics.
Pretreated PDX Models
Established from tumor biopsies from patients pretreated with latest generation therapies
Multi-omic Characterization
Clinical annotations coupled with molecular datasets and in vivo responses
Champions' leading SCLC In Vivo Screen showcases PDX models, each reflecting key clinical characteristics, mutations, and pretreatment history.
-
Clinical history on file for most model including, tumor status, harvest site, smoking history, age, gender and ethnicity.
-
Includes IHC data for crucial mutations such as EGFR and HER2.
-
Model characterization and additional data available for select models, such as WES, RNA-seq, growth data, and in vivo SOC data.
-
Several endpoint data options available including flow cytometry and IHC to quantify target expression and critical phenotypical changes (available upon request).
-
Terminal tumor collections for target validation is available upon request (Snap Frozen/FFPE).
-
No minimum to enroll & 50% off a Standard of Care Agent arm (selected by Champions).